Patents Assigned to Oxigene, Inc.
-
Patent number: 9040500Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: GrantFiled: November 28, 2011Date of Patent: May 26, 2015Assignee: OXiGENE, Inc.Inventors: David Chaplin, Bronwyn G. Siim
-
Patent number: 8877967Abstract: This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.Type: GrantFiled: March 5, 2013Date of Patent: November 4, 2014Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Kishore Kumar Gaddale Devanna, Erica Parker, Kevin G. Pinney, Jiangli Song, Mary Lynn Trawick
-
Publication number: 20130136752Abstract: The present disclosure provides novel ophthalmic formulations for ocular administration comprising a pharmaceutically effective amount of a combretastatin, from 60% to 95% w/w pre-gelatinized starch, from 1% to 10% w/w hydrophilic matrix forming polymer, and from 0.2% to 5% lubricant.Type: ApplicationFiled: August 17, 2012Publication date: May 30, 2013Applicant: OXIGENE, INC.Inventors: Suman Sharma, Bronwyn G. Siim
-
Publication number: 20120270831Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: November 28, 2011Publication date: October 25, 2012Applicant: OXIGENE, INC.Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20120220554Abstract: Methods and compositions for the treatment and prevention of posterior capsular opacification are provided. The method comprises administering a therapeutically effective amount of a combretastatin to a subject suffering from or at risk of developing posterior capsule opacification.Type: ApplicationFiled: January 2, 2012Publication date: August 30, 2012Applicant: OXIGENE, INC.Inventors: Roy Quinlan, Frederique Tholozan
-
Patent number: 8198302Abstract: Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.Type: GrantFiled: March 1, 2004Date of Patent: June 12, 2012Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Klaus Edvardsen, Kevin G. Pinney, Joseph Anthony Prezioso, Mark Wood
-
Publication number: 20110110940Abstract: This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject an ?4?1 integrin antagonist sequentially or simultaneously in combination with said Vascular Disrupting Agent.Type: ApplicationFiled: April 15, 2009Publication date: May 12, 2011Applicant: OXIGENE, INC.Inventors: Robert Kerbel, Yuval Shaked
-
Publication number: 20090192098Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: November 21, 2008Publication date: July 30, 2009Applicant: OXIGENE, INC.Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20090137687Abstract: This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g., by oxidative stress) in order to achieve an enhanced anti-tumor response in a patient.Type: ApplicationFiled: June 19, 2008Publication date: May 28, 2009Applicants: OXiGENE, Inc., Baylor UniversityInventors: David Chaplin, Kevin G. Pinney, Peter Wardman, Vani P. Mocharla, Lisa K. Folkes
-
Patent number: 7456214Abstract: Chrome compounds have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.Type: GrantFiled: May 21, 2004Date of Patent: November 25, 2008Assignees: Baylor University, OXiGENE, Inc.Inventors: Kevin G. Pinney, Phyllis Arthasary, Anupama Shirali, Klaus Edvardsen, David J. Chaplin
-
Patent number: 7384925Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: July 18, 2005Date of Patent: June 10, 2008Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Patent number: 7358236Abstract: The present invention provides a method of using anti-hypertensive agents (“AHAs”) to attenuate the transient increase in blood pressure observed in patients where Vascular Targeting Agents (“VTAs”) are administered to treat diseases associated with malignant neovascularization. The invention also relates to pharmaceutical compositions comprising AHAs and VTAs, and to kits thereof.Type: GrantFiled: June 23, 2003Date of Patent: April 15, 2008Assignee: OXiGENE, Inc.Inventors: David Chaplin, Scott Young
-
Patent number: 7091240Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.Type: GrantFiled: April 29, 2003Date of Patent: August 15, 2006Assignees: Oxigene, Inc., Baylor UniversityInventors: Kevin G. Pinney, Vani P. Mocharla, Zhi Chen, Charles M. Garner, Mallinath Hadimani, Raymond Kessler, James M. Dorsey, Klaus Edvardsen, David J. Chaplin, Joseph Prezioso, Usha Ghatak, legal representative, Anjan Ghatak, deceased
-
Patent number: 7037906Abstract: Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided.Type: GrantFiled: December 20, 2001Date of Patent: May 2, 2006Assignees: Oxigene, Inc., Bristol-Myers Squibb, Inc.Inventor: Francis Y. Lee
-
Patent number: 7001926Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.Type: GrantFiled: April 1, 2003Date of Patent: February 21, 2006Assignees: Oxigene, Inc., Baylor UniversityInventors: Kevin G. Pinney, Vani P. Mocharla, Zhi Chen, Usha R. Ghatak, legal representative, Mallinath Hadimani, Jimmy Kessler, James M. Dorsey, Klaus Edvardsen, David J. Chaplin, Joseph Prezioso, Anjan Ghatak, deceased
-
Patent number: 6956054Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.Type: GrantFiled: August 14, 2002Date of Patent: October 18, 2005Assignees: Baylor University, OXiGENE, Inc.Inventors: Ronald W. Pero, David Sherris, Kevin G. Pinney, Vani P. Mocharla, Zhi Chen
-
Patent number: 6919324Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: October 28, 2002Date of Patent: July 19, 2005Assignees: Oxigene, Inc., Baylor UniversityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Patent number: 6773702Abstract: A method of treating immune suppression in a warm-blooded animal bearing a tumor, by administering to the animal an amount of combretastatin A4 and/or a prodrug thereof effective to enhance immune responsiveness without causing vascular destruction. Immunotherapy treatment to inhibit or kill tumor cells includes administering to the animal an immune-response-stimulating agent such as a vaccine of tumor cells genetically modified to produce an immune-response-enhancing cytokine while counteracting tumor-induced immune suppression in the animal by administering combretastatin A4 and/or a prodrug thereof.Type: GrantFiled: December 26, 2001Date of Patent: August 10, 2004Assignees: OXiGENE, Inc., Bristol-Myers Squibb CompanyInventors: Ronald W. Pero, Francis Y. F. Lee, Klaus Edvardsen, Hans Olov Sjögren
-
Patent number: RE45720Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: February 13, 2014Date of Patent: October 6, 2015Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Patent number: RE45907Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: February 13, 2014Date of Patent: March 1, 2016Assignees: OXiGENE, Inc., Baylor UniverswityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen